For the quarter ending 2026-03-31, TRVI has $179,606K in assets. $7,479K in debts. $19,412K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 19,412 | 18,914 | 56,869 | 117,058 |
| Marketable securities | 152,371 | 169,346 | 138,058 | 86,827 |
| Prepaid expenses | 2,216 | 1,263 | 1,375 | 1,766 |
| Other current assets | 2,122 | 2,133 | 1,997 | 1,577 |
| Total current assets | 176,121 | 191,656 | 198,299 | 207,228 |
| Operating lease right-of-use assets | 610 | 677 | 741 | 804 |
| Property, equipment and leasehold improvements | - | 537 | - | - |
| Less accumulated depreciation and amortization | - | 359 | - | - |
| Property, equipment and leasehold improvements, net | 265 | 178 | 213 | 239 |
| Other non-current assets | 2,610 | 928 | 103 | 68 |
| Finance lease right-of-use assets | - | 0 | 0 | 0 |
| Total assets | 179,606 | 193,439 | 199,356 | 208,339 |
| Finance lease liabilities | - | 0 | 0 | 0 |
| Accounts payable | 2,215 | 3,911 | 2,709 | 2,974 |
| Accrued expenses | 4,582 | 5,531 | 6,036 | 5,981 |
| Operating lease liabilities | 318 | 307 | 296 | 286 |
| Total current liabilities | 7,115 | 9,749 | 9,041 | 9,241 |
| Operating lease liabilities | 364 | 446 | 527 | 605 |
| Total liabilities | 7,479 | 10,195 | 9,568 | 9,846 |
| Common stock 0.001 par value 200,000,000 shares authorized at march 31, 2026 and december 31, 2025 and 128,411,048 and 128,306,056 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 128 | 128 | 128 | 122 |
| Additional paid-in capital | 515,185 | 512,772 | 511,118 | 508,033 |
| Accumulated other comprehensive (loss) income | -190 | 148 | 30 | 24 |
| Accumulated deficit | -342,996 | -329,804 | -321,488 | -309,686 |
| Total stockholders equity | 172,127 | 183,244 | 189,788 | 198,493 |
| Total liabilities and stockholders equity | 179,606 | 193,439 | 199,356 | 208,339 |
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)